What to tell your patients when they ask about Lantus and Cancer

Steve Edelman, MD and Endocrinologist at UCSD in San Diego, CA

 "The recent reports from Europe regarding Lantus being associated with cancer do not represent anything close to a proper scientific..." Full Story 

R. Keith Campbell, PharmD, CDE

"The [study] title may lead people to conclusions that are still very much in doubt. We have become a society where formerly respected publications are now all headlines with little to backup the outlandish claims..." Full Story 

Manuel Sainz De La Pena, MD, Endocrinologist, Diabetes Specialist, Tampa, FL

“I have had at least 50 phone calls this weekand all of the patients want to know what to do..." Full Story 

Ian Blumer, MD, Diabetes Specialist in Toronto, Canada and author of Diabetes for Dummies (Canada)

"Just when those of us in the diabetes community have been riding a wave of reassurance from very recent studies showing favorable rosiglitazone safety results, comes word of studies published in the current issue of Diabetalogia raising the question as to whether insulin glargine (Lantus) may be associated with an increased risk of cancer. The phones are already ringing off the hook as concerned glargine-using patients call to find out what they are to do..." Full Story 

Roland LaJoie, MD, Endocrinologist, St. Petersburg, FL

...who has been in private practice for over 20 years, is telling his patients, "When the articles came out, the American Diabetes Association commented..." Full Story 

Both Steve Freed, our publisher, and I see patients in primary care physician offices almost every day and we are in agreement with all of the comments above, and are telling the clinicians and their patients to keep doing what they have been until we know more.